Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

US PMA (premarket approval) for BSD's RF/microwave-based cancer therapy

This article was originally published in Clinica

Executive Summary

The US FDA has accepted for filing and review BSD Medical's premarket approval (PMA) application for its BSD-2000 cancer treatment system. The product is used to focus therapeutic radiofrequency/microwave heating in cancerous tumours in an effort to kill cancer cells and improve the response of radiation therapy, said the Salt Lake City, Utah firm.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT051823

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel